Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Raven raises $40mm in third round financing

Executive Summary

Monoclonal antibody (MAb) therapeutics developer Raven Biotechnologies closed a $40mm Series C financing round led by Bear Stearns Health Innoventures. Other participants were new investors Pequot Ventures, GE's Life Science and Technology Finance Group, BioMedical Sciences Investment Fund, and Integra Ventures, plus returning investors US Venture Partners, CMEA Ventures, Hambrecht & Quist Capital Management, and Milepost Ventures.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies